Medication info

Rotain Plus F Tablets

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Huons Life Science Co., Ltd.
Appearance
Pale yellow oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 200608373 · Notified 2006.11.07

This product's status changed to Approval withdrawn on 2024.04.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet once daily containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum antihypertensive effect generally occurs approximately 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken without regard to meals. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with separately dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet once daily containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet once daily containing losartan potassium 100 mg/hydrochlorothiazide 25 mg. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet once daily containing losartan potassium 100 mg/hydrochlorothiazide 25 mg. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when blood pressure is controlled at this dose: Treatment may be started with 1 tablet once daily containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg, which can reduce the hydrochlorothiazide dose without reducing the overall antihypertensive effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet once daily containing losartan potassium 100 mg/hydrochlorothiazide 25 mg. ○ Patients with renal impairment Use the usual dose in patients with creatinine clearance of 30 mL/min or higher. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment Use in patients with hepatic impairment requiring dose adjustment is not recommended because the initial dose of losartan potassium for these patients, 25 mg, cannot be administered with this medicine.
Child dose
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children and adolescents.

Ingredients

Manufacturer
Huons Life Science Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This drug is used for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet once daily containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum antihypertensive effect generally occurs approximately 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken without regard to meals. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with separately dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet once daily containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet once daily containing losartan potassium 100 mg/hydrochlorothiazide 25 mg. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet once daily containing losartan potassium 100 mg/hydrochlorothiazide 25 mg. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when blood pressure is controlled at this dose: Treatment may be started with 1 tablet once daily containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg, which can reduce the hydrochlorothiazide dose without reducing the overall antihypertensive effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet once daily containing losartan potassium 100 mg/hydrochlorothiazide 25 mg. ○ Patients with renal impairment Use the usual dose in patients with creatinine clearance of 30 mL/min or higher. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment Use in patients with hepatic impairment requiring dose adjustment is not recommended because the initial dose of losartan potassium for these patients, 25 mg, cannot be administered with this medicine.

Child dose

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children and adolescents.

Precautions

This drug can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so use should be discontinued immediately if pregnancy is confirmed. Those who are allergic to this medicine or its components, have severely impaired kidney function or anuria, have severe liver impairment, or specific electrolyte imbalances should not take this medication. Individuals with special health conditions such as hypotension, kidney disease, liver disease, diabetes, gout, or elderly patients should consult a physician before taking this medication, as it may lower blood pressure excessively. Due to the hydrochlorothiazide component, electrolyte imbalances can occur, necessitating regular blood tests and symptom monitoring, particularly for hypokalemia or hypercalcemia. This drug may interact with other medications; therefore, potassium supplements or medications containing potassium should not be taken arbitrarily and one must consult healthcare providers. Dizziness or drowsiness may occur during treatment, so caution is required when driving or operating machinery. This medication may increase sensitivity to sunlight, requiring sun protection and precautions when going outdoors, and any skin abnormalities should be reported to a doctor immediately. In breastfeeding, this drug may pass into mother’s milk and affect the baby, so breastfeeding should be stopped or discussed with a doctor. Safety has not been established for children and adolescents, so this drug should not be administered to them. In cases of overdose, symptoms such as hypotension or cardiac abnormalities may occur, requiring immediate medical attention; this drug is not removed by hemodialysis. Store this medication in its original container and keep it out of reach of children.

Side effects

  • abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
Show 122 more
  • skin desquamation
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • xerostomia
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • reduced libido
  • memory impairment
  • migraine
  • nervous hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • sleepiness
  • tremors
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • cavernous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste abnormalities
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequent urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • cramps
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • agitation
  • renal failure
  • kidney dysfunction
  • interstitial nephritis
  • mucocutaneous syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • temporary blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • dry cough
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a container that blocks light and air, and it is recommended to store it at room temperature between 1 to 30 degrees Celsius. Storing it this way can help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.